ethyl 5-carbamoylfuran-2-carboxylate | 1239315-93-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 呋喃
• 英文名称: ethyl 5-carbamoylfuran-2-carboxylate
• 英文别名: Ethyl 5-(aminocarbonyl)-2-furancarboxylate
• CAS: 1239315-93-5
• 化学式: C₈H₉NO₄
• 分子量: 183.164
• InChiKey: YTHZUXAGCRQDBW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  82.5
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  5-溴-2-糠酸乙酯 、 三氯乙酰异氰酸酯 在 lithium chloro-isopropyl-magnesium chloride 、 zinc(II) chloride 、 甲醇 、 potassium carbonate 作用下， 以 四氢呋喃 为溶剂， 反应 12.0h， 以78%的产率得到ethyl 5-carbamoylfuran-2-carboxylate
  参考文献：
  名称：

  Preparation of Primary Amides from Functionalized Organozinc Halides

  摘要：

  Organozinc halides, which are prepared either by direct zinc insertion or halogen magnesium exchange and subsequent transmetalation with ZnCl2, react smoothly with commercially available trichloroacetyl isocyanate to give, after hydrolysis, the corresponding primary amides. This method is compatible with a variety of functional groups such as an ester or a cyano group. Also heterocyclic-, alkenyl, and acetylenic zinc reagents are converted to the corresponding primary amides under these conditions.

  DOI：

  10.1021/ol101469f

文献信息

• PYRAZOLE COMPOUNDS AND USE THEREOF
  申请人：Takagi Masaki

  公开号：US20090036450A1

  公开（公告）日：2009-02-05

  The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of the present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specifications.

  本发明的吡唑化合物由以下一般式（I）表示。本发明的吡唑化合物或其盐或溶剂化物强力抑制肝糖原磷酸化酶，因此，可用作糖尿病的治疗或预防剂。其中，每个符号如规范中所述。
• PYRAZOLES AND USE THEREOF AS DRUGS
  申请人：Japan Tobacco Inc.

  公开号：EP2096111A1

  公开（公告）日：2009-09-02

  The pyrazole compound of the present invention is represented by the following general formula (I). The pyrazole compound of present invention or a salt thereof or a solvate thereof potently inhibits liver glycogen phosphorylase, and, therefore, is useful as a therapeutic or prophylactic agent for diabetes. wherein each symbol denotes as described in the specification.

  本发明的吡唑化合物由以下通式（I）表示。本发明的吡唑化合物或其盐或其溶液能有效抑制肝糖原磷酸化酶，因此可用作糖尿病的治疗或预防药物。 其中各符号表示如说明书所述。